How I Treat: Chronic granulomatous disease

Journal of Human Immunity 2026 Open access

Read full text
Authors: Jennifer W. Leiding, Leah Pettiford, Christopher Chang, Aimee Dassner, Mary C. Dinauer, Benjamin Hanisch, Nada Harik, Elizabeth Daly Hicks, Harry L. Malech, Felicia B Morton, Peter E. Newburger, Kathleen E. Sullivan
+2 more Brant R. Ward, Michael D. Keller
DOI: 10.70962/jhi.20250162
Cited by: 3
References: 127

Abstract

Chronic granulomatous disease (CGD) is a rare inborn error of immunity with both high risk of invasive bacterial and fungal infections as well as inflammatory complications. Though diagnostic testing via the dihydrorhodamine assay is widely available, disease recognition can be challenging due to the broad range of initial clinical presentations. Preventative antimicrobial therapy is the backbone of management, while treatment of inflammatory disease remains a challenge. Definitive therapy via hematopoietic stem cell transplantation is increasingly favored for resolution of long-term disease risks, while gene therapy remains a promising but investigational treatment. Here, we present our consensus approach to diagnosis and management of CGD.

Fields of Study & Subjects

Neutrophil Myeloperoxidase and Oxidative Mechanisms Immunodeficiency and Autoimmune Disorders Asthma and respiratory diseases

Publication details

Journal / source
Journal of Human Immunity
Publisher
Rockefeller University Press
Volume
2
Issue
3
Pages
e20250162–e20250162
Publication date
7 March 2026
Language
EN